NDAENTERALSUSPENSION
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
DUOPA (carbidopa and levodopa) by AbbVie is dopa decarboxylase inhibitors [moa]. First approved in 2015.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOPA is a carbidopa and levodopa enteral suspension approved in 2015 for Parkinson's disease patients requiring continuous dopaminergic stimulation. It works by inhibiting DOPA decarboxylase, allowing levodopa to reach the brain where it is converted to dopamine. The enteral suspension formulation provides continuous drug delivery via infusion pump, addressing motor fluctuations in advanced Parkinson's disease.
$3MPart D
PeakDUOPA is in peak commercial phase with modest Part D spending, suggesting a niche specialist product with established but limited market penetration suitable for focused commercial teams.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
Started Jan 2016
213 enrolled
Advanced Parkinson's Disease
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Career Relevance
DUOPA careers center on specialized neurology commercialization and patient support infrastructure in a peak-stage, niche indication product. Roles emphasize healthcare provider relationships, advanced patient education on pump therapy, and market access in specialty neurology practice settings.
Worked on DUOPA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.